B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Girji |
| Almmustuhtton: |
Elsevier,
2021-02-01T00:00:00Z.
|
| Fáttát: | |
| Liŋkkat: | Connect to this object online. |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_e9d5715a259b49d2a1c86d37aa482b0b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Amber Loren O. King, BA |e author |
| 700 | 1 | 0 | |a Fatima N. Mirza, MPH |e author |
| 700 | 1 | 0 | |a Julia M. Lewis, PhD |e author |
| 700 | 1 | 0 | |a Kacie R. Carlson, PA |e author |
| 700 | 1 | 0 | |a Scott Huntington, MD, MPH |e author |
| 700 | 1 | 0 | |a Francine M. Foss, MD |e author |
| 700 | 1 | 0 | |a Michael Girardi, MD |e author |
| 245 | 0 | 0 | |a B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma |
| 260 | |b Elsevier, |c 2021-02-01T00:00:00Z. | ||
| 500 | |a 2352-5126 | ||
| 500 | |a 10.1016/j.jdcr.2020.12.025 | ||
| 546 | |a EN | ||
| 690 | |a BCL-2 | ||
| 690 | |a CTCL | ||
| 690 | |a Sézary syndrome | ||
| 690 | |a venetoclax | ||
| 690 | |a Dermatology | ||
| 690 | |a RL1-803 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n JAAD Case Reports, Vol 8, Iss , Pp 89-92 (2021) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2352512620308857 | |
| 787 | 0 | |n https://doaj.org/toc/2352-5126 | |
| 856 | 4 | 1 | |u https://doaj.org/article/e9d5715a259b49d2a1c86d37aa482b0b |z Connect to this object online. |